Abstract
Dipeptidyl peptidase -4 inhibitors represent a novel way to augment the incretin system and one of the newest class of medications in the treatment of type 2 diabetes mellitus. Their mechanism of action is to decrease the inactivation of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, both of which are involved in maintaining euglycemia subsequent to carbohydrate intake. Currently investigated agents include sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin. Each agent has been shown to provide significant improvements in glycemic control compared to placebo. They are effective when added to other oral diabetes agents and in the cases of sitagliptin, vildagliptin, and alogliptin in addition to insulin. These agents may not provide as significant improvement in glucose concentrations as some other medications including metformin, thiazolidinediones, or glucagon-like peptide 1 agonists. The lack of head to head clinical data comparing the various dipeptidyl peptidase 4 inhibitors does not allow for specific recommendations if one agent is more effective or safer than another within the class. Their side effect profile suggests they are very well tolerated and have few drug interactions. For patients with mildly elevated glucose concentrations, they are therapeutic options in both drug-naïve patients as well as those not optimally controlled on other diabetes medications.
Keywords: Dipeptidyl Peptidase 4 Inhibitors, Incretin, Type 2 diabetes mellitus
Current Diabetes Reviews
Title:An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors
Volume: 8 Issue: 3
Author(s): Brian K. Irons, Jessica M. Weis, Megan R. Stapleton and Krystal L. Edwards
Affiliation:
Keywords: Dipeptidyl Peptidase 4 Inhibitors, Incretin, Type 2 diabetes mellitus
Abstract: Dipeptidyl peptidase -4 inhibitors represent a novel way to augment the incretin system and one of the newest class of medications in the treatment of type 2 diabetes mellitus. Their mechanism of action is to decrease the inactivation of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, both of which are involved in maintaining euglycemia subsequent to carbohydrate intake. Currently investigated agents include sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin. Each agent has been shown to provide significant improvements in glycemic control compared to placebo. They are effective when added to other oral diabetes agents and in the cases of sitagliptin, vildagliptin, and alogliptin in addition to insulin. These agents may not provide as significant improvement in glucose concentrations as some other medications including metformin, thiazolidinediones, or glucagon-like peptide 1 agonists. The lack of head to head clinical data comparing the various dipeptidyl peptidase 4 inhibitors does not allow for specific recommendations if one agent is more effective or safer than another within the class. Their side effect profile suggests they are very well tolerated and have few drug interactions. For patients with mildly elevated glucose concentrations, they are therapeutic options in both drug-naïve patients as well as those not optimally controlled on other diabetes medications.
Export Options
About this article
Cite this article as:
K. Irons Brian, M. Weis Jessica, R. Stapleton Megan and L. Edwards Krystal, An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors, Current Diabetes Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339912800564007
DOI https://dx.doi.org/10.2174/157339912800564007 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Leishmaniasis: A Review and Assessment of Recent Research
Current Pharmaceutical Design Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Resveratrol as a Protective Molecule for Neuroinflammation: A Review of Mechanisms
Current Pharmaceutical Biotechnology Immunobiologic Agents in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Statins and Vulnerable Plaque
Current Pharmaceutical Design The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry TRP Channels in Vascular Disorders
Current Topics in Medicinal Chemistry <i>Lepidium meyenii</i> Supplemented Diet Modulates Neurobehavioral and Biochemical Parameters in Mice Fed High-Fat High-Sugar Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets FoxO Proteins: Regulation and Molecular Targets in Liver Cancer
Current Medicinal Chemistry Wide Pulse Pressure in the Elderly
Current Cardiology Reviews Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study
Current HIV Research Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review
Current Hypertension Reviews The Relationship Between Inflammation, Dyslipidemia and Physical Exercise: From the Epidemiological to Molecular Approach
Current Diabetes Reviews Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review
Current Genomics Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews Application of Human Placental Villous Tissue Explants to Study ABC Transporter Mediated Efflux of 2,4-Dinitrophenyl-S-Glutathione
Current Pharmaceutical Biotechnology Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews